166 related articles for article (PubMed ID: 10737624)
1. Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures.
Moy LY; Zeevalk GD; Sonsalla PK
J Neurochem; 2000 Apr; 74(4):1656-65. PubMed ID: 10737624
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial stress-induced dopamine efflux and neuronal damage by malonate involves the dopamine transporter.
Moy LY; Wang SP; Sonsalla PK
J Pharmacol Exp Ther; 2007 Feb; 320(2):747-56. PubMed ID: 17090704
[TBL] [Abstract][Full Text] [Related]
3. Dopamine mediates striatal malonate toxicity via dopamine transporter-dependent generation of reactive oxygen species and D2 but not D1 receptor activation.
Xia XG; Schmidt N; Teismann P; Ferger B; Schulz JB
J Neurochem; 2001 Oct; 79(1):63-70. PubMed ID: 11595758
[TBL] [Abstract][Full Text] [Related]
4. In vivo vulnerability of dopamine neurons to inhibition of energy metabolism.
Zeevalk GD; Manzino L; Hoppe J; Sonsalla P
Eur J Pharmacol; 1997 Feb; 320(2-3):111-9. PubMed ID: 9059843
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata.
Staal RG; Sonsalla PK
J Pharmacol Exp Ther; 2000 May; 293(2):336-42. PubMed ID: 10773000
[TBL] [Abstract][Full Text] [Related]
6. Protection of malonate-induced GABA but not dopamine loss by GABA transporter blockade in rat striatum.
Zeevalk GD; Manzino L; Sonsalla PK
Exp Neurol; 2002 Jul; 176(1):193-202. PubMed ID: 12093096
[TBL] [Abstract][Full Text] [Related]
7. Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice.
Patel J; Mooslehner KA; Chan PM; Emson PC; Stamford JA
J Neurochem; 2003 May; 85(4):898-910. PubMed ID: 12716422
[TBL] [Abstract][Full Text] [Related]
8. Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine.
Teng L; Crooks PA; Dwoskin LP
J Neurochem; 1998 Jul; 71(1):258-65. PubMed ID: 9648873
[TBL] [Abstract][Full Text] [Related]
9. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
Exp Neurol; 2004 Jul; 188(1):65-73. PubMed ID: 15191803
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons.
German DC; Liang CL; Manaye KF; Lane K; Sonsalla PK
Neuroscience; 2000; 101(4):1063-9. PubMed ID: 11113355
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter.
Jones SR; Gainetdinov RR; Wightman RM; Caron MG
J Neurosci; 1998 Mar; 18(6):1979-86. PubMed ID: 9482784
[TBL] [Abstract][Full Text] [Related]
12. NMDA receptors modulate dopamine loss due to energy impairment in the substantia nigra but not striatum.
Zeevalk GD; Manzino L; Sonsalla PK
Exp Neurol; 2000 Feb; 161(2):638-46. PubMed ID: 10686083
[TBL] [Abstract][Full Text] [Related]
13. Relative vulnerability of dopamine and GABA neurons in mesencephalic culture to inhibition of succinate dehydrogenase by malonate and 3-nitropropionic acid and protection by NMDA receptor blockade.
Zeevalk GD; Derr-Yellin E; Nicklas WJ
J Pharmacol Exp Ther; 1995 Dec; 275(3):1124-30. PubMed ID: 8531072
[TBL] [Abstract][Full Text] [Related]
14. Apparent opposite effects of tetrabenazine and reserpine on the toxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine on nigro-striatal dopaminergic neurons.
Cleren C; Naudin B; Costentin J
Brain Res; 2003 Nov; 989(2):187-95. PubMed ID: 14556940
[TBL] [Abstract][Full Text] [Related]
15. Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration.
Truong JG; Rau KS; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2003 Aug; 474(2-3):223-6. PubMed ID: 12921866
[TBL] [Abstract][Full Text] [Related]
16. Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines.
Burrows KB; Nixdorf WL; Yamamoto BK
J Pharmacol Exp Ther; 2000 Mar; 292(3):853-60. PubMed ID: 10688597
[TBL] [Abstract][Full Text] [Related]
17. 1,2,3,4-Tetrahydroisoquinoline protects terminals of dopaminergic neurons in the striatum against the malonate-induced neurotoxicity.
Lorenc-Koci E; Gołembiowska K; Wardas J
Brain Res; 2005 Jul; 1051(1-2):145-54. PubMed ID: 16004976
[TBL] [Abstract][Full Text] [Related]
18. Damage to dopaminergic nerve terminals in mice by combined treatment of intrastriatal malonate with systemic methamphetamine or MPTP.
Albers DS; Zeevalk GD; Sonsalla PK
Brain Res; 1996 Apr; 718(1-2):217-20. PubMed ID: 8773791
[TBL] [Abstract][Full Text] [Related]
19. Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively.
Alfinito PD; Wang SP; Manzino L; Rijhsinghani S; Zeevalk GD; Sonsalla PK
J Neurosci; 2003 Nov; 23(34):10982-7. PubMed ID: 14645494
[TBL] [Abstract][Full Text] [Related]
20. Endogenous dopamine enhances the neurotoxicity of 3-nitropropionic acid in the striatum through the increase of mitochondrial respiratory inhibition and free radicals production.
Villarán RF; Tomás-Camardiel M; de Pablos RM; Santiago M; Herrera AJ; Navarro A; Machado A; Cano J
Neurotoxicology; 2008 Mar; 29(2):244-58. PubMed ID: 18093658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
